Onconova reports Q2 2023 net loss of $4.3M; cash $29.7M; pipeline updates for narazaciclib and rigosertib

Traws Pharma, Inc.

Net loss of $4.3M ($0.20 per share) vs $4.0M ($0.19) in Q2 2022.
Cash $29.7M as of June 30, 2023; sufficient into Q2 2024.
Topline results from Phase 1/2 narazaciclib studies expected in Q4 2023.
Plans registrational trial for rigosertib in RDEB-SCC after constructive FDA Type B meeting in June.
R&D expense $2.5M, G&A $2.2M for Q2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Traws Pharma, Inc. reported the quarter and six months ended June 30, 2023 results: net income $4.3 million, EPS $0.20 per share.

Period: the quarter and six months ended June 30, 2023
Net income: $4.3 million
EPS: $0.20 per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $4.3 million, or $0.20 per share on 21.0 million weighted shares outstanding, compared with a net loss of $4.0 million, or $0.19 per share for the second quarter of 2022 on 20.9 million weighted shares outstanding.

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089897

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.